AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.135

-0.010-6.90%

Volume:1.96M

Turnover:281.16K

Market Cap:69.26M

PE:-8.23

High:0.147

Open:0.145

Low:0.135

Close:0.145

52wk High:0.275

52wk Low:0.100

Shares:513.07M

Float Shares:351.32M

Volume Ratio:1.45

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.016

EPS(LYR):-0.016

ROE:-25.48%

ROA:-16.29%

PB:1.75

PE(LYR):-8.23

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study

Amplia Signs Collaboration Agreement with Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12c Inhibitor, Olomorasib, in Non-Small Cell Lung Cancer

THOMSON REUTERS

Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly

MT Newswires Live

Amplia Therapeutics - to Begin Study in Late 2026 in Australia and USA

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/ATX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.135,"timestamp":1788156720000,"preClose":0.145,"halted":0,"volume":1955172,"delay":0,"changeRate":-0.06896551724137918,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.0164,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"08-31 16:12:00 AEST","open":0.145,"high":0.147,"low":0.135,"amount":281157,"amplitude":0.082759,"askPrice":0.145,"askSize":72408,"bidPrice":0.135,"bidSize":316622,"shortable":3,"etf":0,"ttmEps":-0.0164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.145,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.4489856659500084,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATX.AU","preClose":0.145,"auctionPrice":0.135,"auctionVolume":139814,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156602130}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-16.29%","roe":"-25.48%","lyrEps":-0.0164,"volumeRatio":1.4489856659500084,"shares":513071629,"dividePrice":0,"high":0.147,"amplitude":0.082759,"preClose":0.145,"low":0.135,"week52Low":0.1,"pbRate":"1.75","psRate":"14.46","week52High":0.275,"institutionHeld":0,"latestPrice":0.135,"committee":0.627751,"eps":-0.0164,"divideRate":0,"volume":1955172,"delay":0,"ttmEps":-0.0164,"open":0.145,"prevYearClose":0.15,"prevWeekClose":0.145,"prevMonthClose":0.135,"prevQuarterClose":0.145,"fiveDayClose":0.15,"twentyDayClose":0.135,"sixtyDayClose":0.12,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656567235","title":"Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2656567235","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656567235?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847551,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics signs trial collaboration with Lilly for narmafotinib-olomorasib NSCLC studyAmplia entered a clinical trial collaboration and supply agreement with Eli Lilly to test narmafotinib w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL4rKcYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","BCDF","NDAQ","ATX.AU","BK7067","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656794556","title":"Amplia Signs Collaboration Agreement with Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12c Inhibitor, Olomorasib, in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656794556","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656794556?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA96JSHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588824","title":"Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588824","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656588824?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:23","pubTimestamp":1785799418,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  struck a collaboration and supply agreement with US-listed pharmaceutical giant Eli Lilly to evaluate an investigational drug combination as a second-line treatment for patients with advanced-stage non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.As part of the deal, a phase 1b/2b clinical trial will assess the safety and efficacy of Amplia's narmafotinib in combination with Eli Lilly's olomorasib, per the filing.Amplia will conduct the trial, which is planned to launch late this year, at sites in Australia and the US. The companies will collaborate to finalize the clinical study protocol and other associated documents.The study extends narmafotinib's clinical development from pancreatic cancer into non-small cell lung cancer, for which the market is currently valued at about $31 billion, Amplia said. It added that narmafotinib showed a range of \"compelling efficacy signals\" across responses and survival in a previous study, with","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999015952.SGD","SG9999014906.USD","LU1023059063.AUD","SG9999014880.SGD","SG9999001176.SGD","SG9999015945.SGD","LU0122379950.USD","LU2237443382.USD","LU1629891620.HKD","IE00B4R5TH58.HKD","LU2750360997.AUD","IE00BFSS7M15.SGD","IE0001KFT4U8.USD","LU0820561818.USD","LU0353189680.USD","LU0882574055.USD","LLII","LU2602419157.SGD","SGXZ99366536.SGD","LU0882574139.USD","LU1291159041.SGD","LU2265009873.SGD","LU2461242641.AUD","LU1868836591.USD","BK4585","LU2111349929.HKD","LU2360106947.USD","IE00B7KXQ091.USD","LU2552382215.SGD","IE0009355771.USD","LU0289739699.SGD","LU2106854487.HKD","LU2168564149.EUR","LU2361044865.SGD","BK7067","IE00BWXC8680.SGD","LU2361045086.USD","LU0823416689.USD","SGXZ51526630.SGD","GB00BDT5M118.USD","LU0203202063.USD","LU0471298694.HKD","LU2089984988.USD","LU0787776722.HKD","LU0417517546.SGD","LU1061106388.HKD","LU1035775433.USD","TMED","SG9999018857.SGD","FHLC","IE00BFTCPJ56.SGD","LU2237443549.SGD","ELIL","LU2237443465.HKD","LU2236285917.USD","LU0320765992.SGD","LU2324357040.USD","LU0345770993.USD","LLY","LU0640476718.USD","LU0456855351.SGD","IE00BKDWB100.SGD","LLYX","RXL","JDOC","BK4516","LU0058720904.USD","LU1323610961.USD","LU2471134523.USD","LU2471134796.USD","THNR","IE00B1XK9C88.USD","LU2462591350.SGD","LU1868837136.USD","LU0320765059.SGD","LU1551013425.SGD","LU0672654240.SGD","IE00B775H168.HKD","LU2168564495.EUR","LU1917777945.USD","PJP","LU0689472784.USD","LU1127390331.HKD","LU1712237335.SGD","LU2108987350.USD","LU0466842654.USD","LU0061475181.USD","LU2750360641.GBP","LU0158827781.USD","LU0820561909.HKD","LU0820562030.AUD","LU0889565916.HKD","LU1267930730.SGD","LU1280957306.USD","LU2271345857.HKD","SG9999014914.USD","BK4533","LU0266013472.USD","IE00BJJMRZ35.SGD","CURE","LU0097036916.USD","LU1623119135.USD","ILDR","BK4007","LU2756315318.SGD","IXJ","LU2023251221.USD","LU0964807845.USD","LU1064131342.USD","LU0114720955.EUR","IE00BJJMRX11.SGD","LU1145028129.USD","LU1868836914.USD","SGXZ57979304.SGD","LLYZ","LU2237438978.USD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","LU2756315664.SGD","IE00BFSS8Q28.SGD","LU1989771016.USD","LU0109391861.USD","LU2491049909.HKD","ELIS","LU0174119429.USD","VHT","LU0203201768.USD","FTXH","LU1983299246.USD","LU0238689110.USD","LU0345770308.USD","OZEM","LU1988902786.USD","LU2456880835.USD","LU1974910355.USD","LU2896262040.SGD","BK4534","LU0943347566.SGD","LU1804176565.USD","LU0385154629.USD","LU2237443895.HKD","LU1868837300.USD","LU2491050071.SGD","SG9999015986.USD","LU2357305700.SGD","LU2361044949.HKD","LU0096364046.USD","LU1720051017.SGD","AGNG","LU1979441026.SGD","LU2168564065.EUR","LU2213496289.HKD","LU2028103732.USD","LU0471298777.SGD","LU0198837287.USD","LU2746668974.SGD","IE00BK4W5M84.HKD","LU0006306889.USD","WDNA","LU0133085943.USD","LU0353189763.USD","LU2746668461.USD","LU1057294990.SGD","MHIP","LU1548497426.USD","LU0234572021.USD","IE0005OL40V9.USD","LU1093756168.USD","LU0432979614.USD","LU2471134879.HKD","IE00BK4W5L77.USD","LU2063271972.USD","LU1720051108.HKD","LU2168563687.JPY","LU2087625088.SGD","SG9999013999.USD","BK4581","IE00B1BXHZ80.USD","LU1366192091.USD","LU0256863811.USD","LU2112291526.USD","LU2237443622.USD","LU2023250504.SGD","IE00B2B36J28.USD","LU0109394709.USD","LU0158827948.USD","LU0683600562.USD","LU0354030438.USD","LU1868836757.USD","LU2089283258.USD","LU0316494557.USD","LU2237443978.SGD","SG9999001176.USD","HRTS","IE00BN29S564.USD","LU2491050154.USD","LU2417539215.USD","SG9999017495.SGD","MEDX","TRUH","IE0002141913.USD","IE00BJJMRY28.SGD","LU0708995401.HKD","SG9999014898.SGD","GDOC","LU1551013342.USD","IE00BKPKM429.USD","BK4599","LU2211815571.USD","LU2264538146.SGD","LU2468319806.SGD","LU2552382058.USD","LU2471134952.CNY","MEDI","LU2552382132.HKD","LU0786609619.USD","LU2462157665.USD","BK4588","LU1069344957.HKD","LU0823434583.USD","SG9999015978.USD","XLV","SG9999018865.SGD","LU0354030511.USD","LU2023250330.USD","IE00B4JS1V06.HKD","SGXZ81514606.USD","IHE","LU0256863902.USD","SGXZ31699556.SGD","PPH","IE0004445239.USD","LU0094547139.USD","CANC","IYH","IE0004445015.USD","LU0106261372.USD","ATX.AU","LU0823434740.USD","LU1093756325.SGD","LU1232071149.USD","LU1814569148.SGD","LU2089284900.SGD","LU2168564222.USD","LU0323591593.USD","LU0210536198.USD","LU0079474960.USD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300583","title":"Amplia Therapeutics - to Begin Study in Late 2026 in Australia and USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300583?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:22","pubTimestamp":1785795752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUE1KKBYJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}